[Answered] Which behavior should a presenter avoid during the oral presentation? a. using jargon b. ...

This topic contains a solution. Click here to go to the answer

Author Question: Which behavior should a presenter avoid during the oral presentation? a. using jargon b. ... (Read 104 times)

student77

Hero Member
Posts: 567

on: Jun 28, 2018

Which behavior should a presenter avoid during the oral presentation?
a. using jargon
b. maintaining eye contact
c. repeating the main points
d. using short, familiar words

Question 2

__________ are mostly comprised of experience and credence qualities.
a. Products
b. Services
c. Purchases
d. Goods

Need homework help now?

Ask unlimited questions for free

Ask a Question

Marked as best answer by a Subject Expert

apple

Sr. Member
Posts: 352

Reply #1 on: Jun 28, 2018

Answer to Question 1

A

Answer to Question 2

b

student77

Member
Posts: 567

Reply 2 on: Jun 28, 2018

Great answer, keep it coming

6ana001

Member
Posts: 311

Reply 3 on: Yesterday

Gracias!

« previous next »

Did you know?

In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.

Did you know?

Between 1999 and 2012, American adults with high total cholesterol decreased from 18.3% to 12.9%

Did you know?

Of the estimated 2 million heroin users in the United States, 600,000–800,000 are considered hardcore addicts. Heroin addiction is considered to be one of the hardest addictions to recover from.

Did you know?

When intravenous medications are involved in adverse drug events, their harmful effects may occur more rapidly, and be more severe than errors with oral medications. This is due to the direct administration into the bloodstream.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.